Trevi Therapeutics, Inc.

NASDAQ:TRVI

Biotechnology

Healthcare
$13.51 +2.63%

+$0.43 today

Market cap
$1.93B
Beta
1.05
P/E (TTM)
-53.6
EPS (TTM)
-$0.31
52W Low $5.41High $17.10

Volume 2.02M

Average 1.44M

TRVI Accounts Payables

Cash effect of the change in amounts owed to suppliers; growing payables preserve cash.

Trevi Therapeutics, Inc.NASDAQ: TRVI

Accounts Payables · Q3 FY2026 · quarter ended Sep 2026

Accounts payables growth accelerates

Q3 FY2026 accounts payables of $451K (cash outflow) rose 59.9% year over year, ahead of the -293.6% change in trailing-twelve-month accounts payables. Sequentially, it rose 63.4% from the prior quarter.

Context

  • Accounts payables increased in 1 of the last 3 fiscal years.

What to watch

Whether quarterly growth of +59.9% holds above the trailing-twelve-month pace of -293.6%.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterSep 2026
-$451K+63.4% QoQ
Last fiscal yearDec 2025
-$598K-137.3% YoY
LTMSep 2026
-$2.09M-293.6% YoY
Accounts Payables past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+59.9%——
1 year-137.3%——
3-year CAGR———
5-year CAGR——
10-year CAGR——

Accounts Payables history

USD · from the cash flow

Latest · FY2025
(598K) USD
Year-over-year change
-137.3%

Accounts Payables vs competitors

How TRVI compares with its peers on the latest reported figures

  • Peers report in different currencies, so accounts payables is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of -293.6% is the 6th highest of 8, against a peer median of -190.0%.
TRVI Competitors
Accounts Payables for TRVI and competitors
Company Period LTM YoY 3-year CAGR% of revenue
ACADACADIA Pharmaceuticals Inc.LTM Jun 2026$24.47M USD+11282.3%—2.1%
LXRXLexicon Pharmaceuticals, Inc.LTM Mar 2026$15.43M USD-795.9%—22.2%
LQDALiquidia CorporationLTM Jun 2026$11.7M USD-361.8%—2.6%
TENXTenax Therapeutics, Inc.LTM Mar 2026$5.78M USD+397.4%——
RAPPRapport Therapeutics, Inc. Common StockLTM Mar 2026$4.34M USD+345.5%—21.7%
UPBUpstream Bio, Inc.LTM Mar 2026$3.01M USD-190.0%—90.5%
TRVITrevi Therapeutics, Inc.LTM Sep 2026$2.09M USD-293.6%——
TBPHTheravance Biopharma, Inc.LTM Mar 2026$1.31M USD-278.7%—1.2%
VCREVicore Pharma Holding ABLTM Jun 2026SEK 0 SEK——0.0%
Peer median (excluding TRVI) —-190.0%—2.6%

Competitors are the stored peer set for TRVI. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(33.94M)(29.15M)(29.07M)(47.91M)(42.76M)
Depreciation & Amortization50K43K123K147K144K
Deferred Income Tax(82K)0000
Stock-Based Compensation2.54M2.33M2.25M3.59M5.19M
Change in Working Capital1.51M(1.23M)(3.85M)6.83M(3.49M)
Accounts Receivables00000
Inventory00000
Accounts Payables831K9K(1.05M)1.61M(598K)
Other Working Capital678K(1.24M)(2.8M)5.22M(2.89M)
Other Non-Cash Items974K(162K)(1.17M)(907K)(1.17M)
Operating Cash Flow(28.95M)(28.18M)(31.71M)(38.26M)(42.09M)
Capital Expenditures0(159K)(137K)(35K)(12K)
Acquisitions (Net)0(829K)000
Purchases of Investments0(126.22M)(9.93M)(98.46M)(170.66M)
Sales of Investments019M69.5M75.6M74.93M
Other Investing Activities0829K01.37M1.64M
Investing Cash Flow0(107.37M)59.43M(21.53M)(94.11M)
Debt Repayment(68K)(5.83M)(9.41M)(126K)0
Common Stock Issued21.18M105.41M1.71M61.15M120.3M
Common Stock Repurchased00000
Dividends Paid00000
Other Financing Activities(340K)11.73M(211K)464K714K
Financing Cash Flow20.78M111.31M(7.91M)61.48M121.01M
Effect of Forex Changes00000
Net Change in Cash(8.17M)(24.24M)19.81M1.7M(15.18M)
Free Cash Flow(28.95M)(28.33M)(31.85M)(38.29M)(42.1M)

Trevi Therapeutics, Inc.

NASDAQ:TRVI

Intrinsic Alpha fair value

Locked

Current Price

$13.51

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.